Introduction
Chlamydia trachomatis is among the most prevalent sexually transmitted diseases in the United States, accounting for an estimated four million cases each year.' These infections are often asymptomatic, but are associated with substantial morbidity in men, women, and infants. This is particularly true for women, in whom the sequelae of chlamydial upper genital tract infection (endometritis and salpingitis) include tubal infertility and ectopic pregnancy.23 One impediment to effective treatment of chlamydial infections has been the need for patients to take seven or more days of multidose therapy, usually with antibiotics which have at least moderate gastrointestinal side effects. Consequently, some symptomatic patients are noncompliant, especially after they improve with partial therapy. Compliance with multiple day therapy is even more difficult in asymptomatic patients and may result in treatment failure. Treatment failures may then be responsible for persistent infections and reinfection of sexual partners.
Azithromycin is an azalide antibiotic that has a minimum inhibitory concentration (MIC) against C trachomatis of 0.03 to 0-25 mg/145 and achieves high intracellular concentrations, which may be beneficial in eradicating chlamydia, a known obligate intracellular pathogen.6 In addition, azithromycin has good in vitro activity against other sexually transmitted pathogens that are often present concurrently, including Ureaplasma urealyticum. 7 Finally, azithromycin has tissue bioavailability and a tissue half-life of between two and four days.8 These (table 1) showed no significant differences between the two treatment groups. Of the 597 patients who received study medication, 349 (87%) azithromycin and 165 (85%) doxycycline subjects completed the two-week study period. Eighty three enrolled participants discontinued or were dropped from study participation for a variety of reasons, including poor compliance with the study protocol (57), protocol violation (12), failure to meet entry criteria (8) , and other reasons (6). Ten azithromycin-treated patients and two doxycycline-treated patients were reported to have elevations in results of liver function tests during the study. Two patients who received azithromycin had elevated liver enzymes at the second follow-up visit. One patient who received doxycycline and one azithromycin patient had elevated alanine aminotransferase (ALT) levels at their last study visits, but were lost to follow-up. Prior to the end of the study, all liver function abnormalities returned to normal in the remaining patients.
Two patients became pregnant while enrolled in the study; both received azithromycin. One patient elected to terminate the pregnancy for reasons other than study participation. The other patient carried the pregnancy to term and delivered a healthy infant.
Discussion
In this randomised, comparative trial, a single 1 g dose of azithromycin was as effective as the seven-day doxycycline regimen for the treatment of uncomplicated cervical and urethral infections caused by C trachomatis. The outcomes observed for seven days of doxycycline therapy are consistent with the results reported in previous multicentre studies of uncomplicated chlamydial infections.'3 14 The observed cure rates in excess of 90% are likewise consistent with those from other reports of singledose therapy with azithromycin for treatment of uncomplicated chlamydial lower genital tract infections.9 12 Our study differs from other USA trials of azithromycin in two major ways: (1) the use of non-culture chlamydia detection tests to identify cases and to assess bacteriological outcome; and (2) the trial was conducted outside of the usual academic setting. Additionally, the final follow-up assessments were made only two weeks after enrolment, as opposed to the usually recommended four or more weeks.
In this study, nearly 600 patients were enrolled primarily at sites providing regular clinical care rather than at university-based research centres. The number and diversity of study sites were substantially greater in this trial than in an earlier reported study9 and serve to validate the efficacy of azithromycin in a "realworld" setting. The use of primary care settings outside of university centres, as in this study, provides evidence that azithromycin can be successfully used to treat chlamydia infection in such primary care settings. In comparison with the earlier study, a major difference in outcome in this study was that adverse events were approximately twice as common for both drugs.
Whether this difference represents a true difference in the proportion of patients experiencing adverse events, a difference in how questions to elicit adverse events were asked, or simply differences in the populations studied is unknown. As there was no specified methodology for eliciting adverse events, some investigators may have been more intensive than others in their questioning of patients.
A second difference between this and earlier studies was the use of non-culture antigen detection assays for identification of cases and evaluation of bacteriological outcomes. While these tests are somewhat less sensitive than optimally performed cell cultures, logistical issues such as specimen transport, limited access to culture media, and cost considerations combine to make non-culture methods most likely to be used for chlamydia diagnosis in private offices and outpatient clinics. Among symptomatic women and men, their sensitivity ranges from 60-92%.'5 More recent generations of commercially available non-culture tests now have a specificity comparable to cell culture (98-100%). Using a variety of commercially available rapid detection tests two weeks following initiation of therapy, bacteriological response to therapy in this study was 97% and 99% in azithromycin and doxycycline-treated patients, respectively. These results are very similar to previously published reports in which culture methods were utilised, primarily at university-based centres and suggest that the use of rapid non-culture diagnostic techniques for evaluating therapeutic regimens is a reasonable alternative when cultures for C trachomatis are not available.
An additional concern which might be raised regarding this study would be the adequacy of the two-week follow-up for assessing response to therapy for chlamydial infections. Previous trials comparing ciprofloxacin to doxycycline for the treatment of nongonococcal urethritis revealed late treatment failures that were identified three weeks or more after completion of therapy by a sensitive culture system.'6 '7 Of some concern in this study was the consideration that false-negative tests of cure might arise if a treatment regimen simply reduced the number of organisms below the detection limit of an insensitive antigen detection assay. However, the results of the current study nearly parallel those of the previously published report,9 where virtually the same number of treatment failures was detected in the two and four week followup evaluations as at the one and two-week evaluations in the present study.
While further study is needed, our results suggest that follow-up using non-culture tests at two weeks after treatment accurately predicts bacteriological cure. Of interest were the 33 patients who were judged clinically cured but who had positive assay tests at week one. These cases most likely represent prolonged antigen excretion after apparent eradication of the organism, but they may be a source of confusion if a two week assessment of response to therapy using non-culture tests had not been used. However, given the high efficacy of both of these treatment regimens, the 1993 
